vimarsana.com

Page 2 - அஹமதாபாத் அடிப்படையிலானது ஜய்துச் காடிலா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AIIMS Delhi to begin Covaxin second dose trial on 2-6 age group next week

New Delhi: Children during the launch of a mobile vaccination centre The All India Institute of Medical Sciences (AIIMS) in Delhi is all set to conduct the trial of Covaxin s second dose on children aged 2-6 years. The trial will begin next week. AIIMS had previously vaccinated children aged 6-12 with the second dose of Bharat Biotech s Covaxin.  Trials for coronavirus vaccine for children are underway in the country ahead of an anticipated third wave of the pandemic. Earlier, Dr Randeep Guleria, AIIMS director, had informed that the Covid-19 vaccine for children could become available in September. AIIMS Delhi is one of the centers to conduct vaccine trials on the below 18 age group.

What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India

What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India Firstpost 16 hours ago FP Staff © Provided by Firstpost What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India Editor s note: This piece has been replugged because there are reports that India has been offered 7.5 million doses of Moderna s COVID-19 vaccine through the COVAX global vaccine sharing programme but the consensus on the indemnity clause has added an element of uncertainty on the arrival of vaccines. Vaccine manufacturers Moderna and Pfizer are ready to supply their COVID-19 vaccines to India provided the Government of India gives them indemnity against any liabilities from the usage of their vaccines.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.